T

Tubulis GmbH Tech Stack

Protein-drug conjugate developer advancing ADC therapies through clinical trials

Biotechnology Research Munich, Bayern 51–200 employees Privately Held

Tubulis develops antibody-drug conjugates (ADCs) using proprietary protein-conjugation technology paired with disease-specific biology. The hiring mix—heavily weighted toward healthcare, research, and regulatory leadership roles—combined with active projects spanning global clinical trials, GCP/GLP compliance, and regulatory strategy, reveals a company scaling from discovery into late-stage development and regulatory submission. Pain points around clinical trial execution, GMP scale-up, and regulatory timing confirm a biotech moving from bench to clinic.

Tech Stack 11 technologies

Core StackPython Microsoft Office Veeva HPLC SDS-PAGE R Monolix Phoenix WinNonlin Microsoft Project Excel PowerPoint

What Tubulis GmbH Is Building

◆Challenges

Developing novel therapies
Ensuring compliance with gcp/glp regulations
Scale-up to gmp sites
Delays in data entry at clinical sites
Timely execution of regulatory responses
Risk monitoring and mitigation
Managing global clinical trials
Managing vendor qualification programs
Optimizing clinical trial processes
Identifying process bottlenecks

▲Active Projects

Global clinical trials of adcs
Adc global clinical trial documentation
Global gcp audit program
Characterization of adc assets
Adc global clinical trial development
Protocol amendment writing
Clinical trial data review
Qms for gcp/glp
Global regulatory strategy development
Regulatory submission coordination

Hiring Activity

Accelerating20 roles · 15 in 30d

Department

Healthcare

7

Research

6

Manufacturing

2

Ops

2

Quality

2

Cmc

1

Clinical

1

HR

1

Seniority

Senior

16

Manager

2

Mid

2

Director

1

Junior

1

Notable leadership hires: Medical Director, Regulatory Affairs Director, Inspection Lead

Company intelligence

Find more companies like Tubulis GmbH by tech stack, pain points and active projects

Get started free

About Tubulis GmbH

Tubulis is a Munich-based biotech company developing next-generation antibody-drug conjugates by combining proprietary conjugation platforms with targeted disease biology. The company operates across discovery, manufacturing, and clinical development, with a tech stack spanning analytical chemistry (HPLC, SDS-PAGE), statistical modeling (Monolix, Phoenix WinNonlin), and lab management software (Veeva). Current operations span Germany, the UK, and the US, with active recruitment focused on clinical operations, regulatory affairs, quality assurance, and CMC roles—indicative of advancement into multi-site clinical trial execution and regulatory submissions.

HeadquartersMunich, Bayern

Company Size51–200 employees

Hiring MarketsGermany, United Kingdom, United States

Frequently Asked Questions

What is Tubulis working on?

Tubulis is running global clinical trials for ADC therapies, building GCP/GLP compliance systems, scaling manufacturing to GMP-certified sites, and executing regulatory strategies and submissions. Active projects include protocol amendments, clinical trial data review, and vendor qualification programs.

What tech stack does Tubulis use?

Core tools include Veeva (regulatory/lab management), HPLC and SDS-PAGE (analytical chemistry), Monolix and Phoenix WinNonlin (statistical pharmacokinetics modeling), and R and Python (data analysis). Microsoft Office and Project support operations.